Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs that target sirtuins, a family of enzymes that promote the body's natural defense against disease. These enzymes, also known as class III histone deacetylases (HDACs), are attractive drug targets for diseases associated with aging, including metabolic and neurological diseases. The company's primary focus is on developing drugs to treat metabolic diseases such as Type 2 Diabetes. Sirtris Pharmaceuticals aims to provide novel therapeutics that modulate sirtuins and enhance the body's ability to combat age-related diseases.